{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:00:43Z","timestamp":1715580043317},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1007\/s11906-004-0029-1","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T20:32:10Z","timestamp":1179952330000},"page":"327-330","source":"Crossref","is-referenced-by-count":13,"title":["Aldosterone-receptor antagonism and end-stage renal disease"],"prefix":"10.1007","volume":"6","author":[{"given":"Niall","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd W. B.","family":"Gehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenic A.","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"29_CR1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM197203022860901","volume":"286","author":"HR Brunner","year":"1972","unstructured":"Brunner HR, Laragh JH, Baer L, et al.: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286:441\u2013449.","journal-title":"N Engl J Med"},{"key":"29_CR2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","volume":"324","author":"MH Alderman","year":"1991","unstructured":"Alderman MH, Madhavan S, Ooi WL, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"29_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"SOLVD Investigators 1992","year":"1992","unstructured":"SOLVD Investigators 1992: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1992, 327:685\u2013691.","journal-title":"N Engl J Med"},{"key":"29_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669\u2013677.","journal-title":"N Engl J Med"},{"key":"29_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensinconverting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145\u2013153.","journal-title":"N Engl J Med"},{"key":"29_CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001, 135:73\u201387.","journal-title":"Ann Intern Med"},{"key":"29_CR7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995\u20131003.","journal-title":"Lancet"},{"key":"29_CR8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860.","journal-title":"N Engl J Med"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667\u20131675.","journal-title":"N Engl J Med"},{"key":"29_CR10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","volume":"21","author":"Guidelines Committee","year":"2003","unstructured":"Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011\u20131053.","journal-title":"J Hypertens"},{"key":"29_CR11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206\u20131252.","journal-title":"Hypertension"},{"key":"29_CR12","first-page":"2996","volume":"104","author":"SA Hunt","year":"2001","unstructured":"Hunt SA, Baker DW, Chin MH, et al.: ACC\/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines Circulation 2001, 104:2996\u20133007.","journal-title":"A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines Circulation"},{"key":"29_CR13","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000013952.86046.DD","volume":"105","author":"SM Grundy","year":"2002","unstructured":"Grundy SM, Howard B, Smith S Jr, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231\u20132239.","journal-title":"Circulation"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","volume":"37","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ: Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047\u20131052.","journal-title":"Hypertension"},{"key":"29_CR15","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849\u20131865.","journal-title":"Circulation"},{"key":"29_CR16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","volume":"35","author":"Y Sun","year":"1997","unstructured":"Sun Y, Ramires FJ, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997, 35:138\u2013147.","journal-title":"Cardiovasc Res"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1523-1755.2000.00973.x","volume":"57","author":"C Delcayre","year":"2000","unstructured":"Delcayre C, Silvestre JS, Garnier A, et al.: Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000, 57:1346\u20131351.","journal-title":"Kidney Int"},{"key":"29_CR18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004872-200103001-00017","volume":"19","author":"Y Takeda","year":"2001","unstructured":"Takeda Y, Yoneda T, Demura M, et al.: Effects of high sodium intake on cardiovascular aldosterone synthesis in strokeprone spontaneously hypertensive rats. J Hypertens 2001, 19:635\u2013639.","journal-title":"J Hypertens"},{"key":"29_CR19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.HYP.25.2.170","volume":"25","author":"Y Takeda","year":"1995","unstructured":"Takeda Y, Miyamori I, Yoneda T, et al.: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170\u2013173.","journal-title":"Hypertension"},{"key":"29_CR20","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","volume":"143","author":"R Rocha","year":"2002","unstructured":"Rocha R, Martin-Berger CL, Yang P, et al.: Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143:4828\u20134836.","journal-title":"Endocrinology"},{"key":"29_CR21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000066348","volume":"25","author":"AU Yalcin","year":"2002","unstructured":"Yalcin AU, Dincer M, Aslan V, Gulbas Z: Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002, 25:260\u2013264.","journal-title":"Kidney Blood Press Res"},{"key":"29_CR22","first-page":"230","volume":"15","author":"NJ Brown","year":"2002","unstructured":"Brown NJ, Vaughan DE, Fogo AB: Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002, 15:230\u2013235.","journal-title":"J Nephrol"},{"key":"29_CR23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","volume":"63","author":"I Feria","year":"2003","unstructured":"Feria I, Pichardo I, Juarez P, et al.: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003, 63:43\u201352.","journal-title":"Kidney Int"},{"key":"29_CR24","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345:1689\u20131697. Comprehensive discussion on the role of aldosterone in myocardial structure and function particularly as relates to congestive heart failure.","journal-title":"N Engl J Med"},{"key":"29_CR25","first-page":"1863","volume":"85","author":"CE Fardella","year":"2000","unstructured":"Fardella CE, Mosso L, G\u00f3mez-S\u00e1nchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863\u20131867.","journal-title":"J Clin Endocrinol Metab"},{"key":"29_CR26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/014107680109400803","volume":"94","author":"M Epstein","year":"2001","unstructured":"Epstein M: Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001, 94:378\u2013383.","journal-title":"J R Soc Med"},{"key":"29_CR27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896.","journal-title":"Hypertension"},{"issue":"SuppN","key":"29_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","volume":"16","author":"A Struthers","year":"1995","unstructured":"Struthers A: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 1995, 16(SuppN):103\u2013106.","journal-title":"Eur Heart J"},{"key":"29_CR29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ki.1993.170","volume":"43","author":"M Allon","year":"1993","unstructured":"Allon M: Treatment and prevention of hyperkalemia in end-stage renal disease. Kidney Int 1993, 43:1197\u20131209.","journal-title":"Kidney Int"},{"key":"29_CR30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0272-6386(12)80110-7","volume":"18","author":"MM Salem","year":"1991","unstructured":"Salem MM, Rosa RM, Battle DC: Extra renal potassium tolerance in chronic renal failure: implications for the treatment of hyperkalemia. Am J Kid Dis 1991, 18:421\u2013440.","journal-title":"Am J Kid Dis"},{"key":"29_CR31","first-page":"197","volume":"1","author":"M Papadimitriou","year":"1983","unstructured":"Papadimitriou M, Vyzantiadis A, Milionis A, et al.: The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Syst 1983, 1:197\u2013205.","journal-title":"Life Support Syst"},{"key":"29_CR32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1081\/JDI-100108195","volume":"23","author":"D Vlassopoulos","year":"2001","unstructured":"Vlassopoulos D, Sonikian M, Dardioti V, et al.: Insulin and mineralocorticoid influence on extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail 2001, 23:833\u2013842.","journal-title":"Ren Fail"},{"key":"29_CR33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.1988.194","volume":"34","author":"A Sugarman","year":"1988","unstructured":"Sugarman A, Brown RS: The role of aldosterone in potassium tolerance: studies in anephric humans. Kidney Int 1988, 34:397\u2013403. Carefully conducted studies exploring the controlling influences on serum potassium in anephric dialysis patients.","journal-title":"Kidney Int"},{"key":"29_CR34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","volume":"12","author":"A Sato","year":"1999","unstructured":"Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end stage renal failure treated with haemodialysis. Am J Hypertens 1999, 12:867\u2013873.","journal-title":"Am J Hypertens"},{"key":"29_CR35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-9343(03)00293-6","volume":"115","author":"K Nitta","year":"2003","unstructured":"Nitta K, Akiba T, Nihei H: Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003, 115:250.","journal-title":"Am J Med"},{"key":"29_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0016-5085(85)80130-X","volume":"88","author":"ES Foster","year":"1985","unstructured":"Foster ES, Jones WJ, Hayslett JP, et al.: Role of aldosterone and dietary potassium in potassium adaptation in the distal colon of the rat. Gastroenterology 1985, 88:41\u201346.","journal-title":"Gastroenterology"},{"key":"29_CR37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ki.1992.284","volume":"42","author":"CP Bastl","year":"1992","unstructured":"Bastl CP, Hayslett JP: The cellular action of aldosterone in target epithelia [editorial]. Kidney Int 1992, 42:250\u2013264.","journal-title":"Kidney Int"},{"key":"29_CR38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/cs0730247","volume":"73","author":"GI Sandle","year":"1987","unstructured":"Sandle GI, Gaiger E, Tapster S, Goodship TH: Evidence for large intestinal control of potassium homeostasis in uremic patients undergoing long-term dialysis. Clin Sci 1987, 73:247\u2013252.","journal-title":"Clin Sci"},{"key":"29_CR39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1507\/endocrj1954.36.681","volume":"36","author":"K Matsuda","year":"1989","unstructured":"Matsuda K, Shimamoto K, Ura N, et al.: A case of primary aldosteronism with chronic renal failure undergoing hemodialysis treatment. Endocrinol Jpn 1989, 36:681\u2013686.","journal-title":"Endocrinol Jpn"},{"key":"29_CR40","first-page":"151","volume":"37","author":"RC Charron","year":"1969","unstructured":"Charron RC, Leme CE, Wilson DR, et al.: The effect of adrenal steroids on stool composition as revealed by in vivo dialysis of feces. Clin Sci 1969, 37:151\u2013167.","journal-title":"Clin Sci"},{"key":"29_CR41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/DMDI.1987.5.4.273","volume":"5","author":"HW Overdiek","year":"1987","unstructured":"Overdiek HW, Merkus FW: The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact 1987, 5:273\u2013302.","journal-title":"Rev Drug Metab Drug Interact"},{"key":"29_CR42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","volume":"29","author":"P Gardiner","year":"1989","unstructured":"Gardiner P, Schrode K, Quinlan D, et al.: Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989, 29:342\u2013347.","journal-title":"J Clin Pharmacol"},{"key":"29_CR43","first-page":"P37","volume":"75","author":"WR Ravis","year":"2004","unstructured":"Ravis WR, Reid S, Roniker B, et al.: Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. Clin Pharmacol Ther 2004, 75:P37.","journal-title":"Clin Pharmacol Ther"},{"key":"29_CR44","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/17.11.2035","volume":"17","author":"MJ Hausmann","year":"2002","unstructured":"Hausmann MJ, Liel-Cohen N: Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 2002, 17:2035\u20132036.","journal-title":"Nephrol Dial Transplant"},{"key":"29_CR45","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/ndt\/gfg413","volume":"18","author":"S Hussain","year":"2003","unstructured":"Hussain S, Dreyfus DE, Marcus RJ, et al.: Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003, 18:2364\u20132368. Small patient series exploring the likelihood of developing hyperkalemia in end-stage renal disease patients exposed to spironolactone under protocol-driven conditions.","journal-title":"Nephrol Dial Transplant"},{"key":"29_CR46","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","volume":"18","author":"P Saudan","year":"2003","unstructured":"Saudan P, Mach F, Perneger T, et al.: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003, 18:2359\u20132363. One of the first series reporting on the safety of spironolactone in the end-stage renal disease patient population, albeit under rather controlled conditions.","journal-title":"Nephrol Dial Transplant"},{"key":"29_CR47","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/0002-9149(93)90244-7","volume":"71","author":"DC Schohn","year":"1993","unstructured":"Schohn DC, Jahn HA, Pelletier BC: Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993, 71:40A-50A.","journal-title":"Am J Cardiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0029-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-004-0029-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0029-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:16:08Z","timestamp":1559420168000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-004-0029-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s11906-004-0029-1","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}